Loading
A phase 2 trial of KC1036 in ewing sarcoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma is a phase 2 interventional study registered as NCT06564272 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-04-01. Interventions recorded: KC1036. Conditions listed: Ewing Sarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/